Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 3/20 | 0.70 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.62 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.62 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | OGG1 | O15527 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095373 | 0.82 | PLOD2 (0.72) | PLOD2PLOD3PLOD1MAPTRECQL | |
| SCHEMBL711849 | 0.82 | PLOD2 (1.00) | PLOD2PLOD3PLOD1CES2CES1 | |
| SCHEMBL4599442 | 0.82 | PLOD2 (0.49) | PLOD2PLOD3PLOD1GSK3BHAO1 | |
| SCHEMBL1305020 | 0.81 | GSK3B (0.70) | GSK3BHAO1HDAC1HDAC8HDAC3 | |
| SCHEMBL28425950 | 0.81 | HAO1 (0.56) | PLOD2GSK3BHAO1HDAC1HDAC8 | |
| SCHEMBL313164 | 0.81 | PLOD2 (0.70) | PLOD2PLOD3PLOD1GSK3BHDAC1 | |
| SCHEMBL1593867 | 0.81 | PLOD2 (0.70) | PLOD2PLOD3PLOD1GSK3BHDAC1 | |
| SCHEMBL5798569 | 0.81 | PLOD2 (0.70) | PLOD2PLOD3PLOD1GSK3BCES1 | |
| SCHEMBL584065 | 0.81 | PLOD2 (0.70) | PLOD2PLOD3PLOD1GSK3BCES2 | |
| SCHEMBL5272209 | 0.80 | HDAC1 (0.54) | PLOD2GSK3BHDAC1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917908-B1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | COUNCIL SCIENT IND RES (IN) | 2024-08-14 | — | — | EP | claimed |
| US-11802112-B2 | Continuous flow micro-total process system for preparation of celecoxib and analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-10-31 | — | — | US | claimed |
| US-20220127235-A1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYTEM FOR PREPARATION OF CELCOXIB AND ANALOGS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-04-28 | — | — | US | claimed |
| EP-3917908-A1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | Council of Scientific & Industrial Research (IN) | 2021-12-08 | — | — | EP | claimed |
| WO-2020157771-A1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-08-06 | — | — | WO | claimed |
| EP-2417216-A2 | MODIFICATION OF LAYERED SILICATES FOR LUMINESCENCE ACTIVATION | Inbio Prof. Jürgen Büddefeld Dr. Peter Klauth Prof. Manfred Rietz Gbr (DE) | 2012-02-15 | — | — | EP | claimed |
| WO-2010115503-A2 | MODIFICATION OF LAYERED SILICATES FOR LUMINESCENCE ACTIVATION | INBIO PROF. JÜRGEN BÜDDEFELD DR. PETER KLAUTH PROF. MANFRED RIETZ GBR (DE) | 2010-10-14 | — | — | WO | claimed |
| EP-3917908-B1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | COUNCIL SCIENT IND RES (IN) | 2024-08-14 | — | — | EP | disclosed |
| US-20240033363-A1 | ALC1 Inhibitors and Synergy with PARPi | EISBACH BIO GMBH (DE) | 2024-02-01 | — | — | US | disclosed |
| US-11802112-B2 | Continuous flow micro-total process system for preparation of celecoxib and analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-10-31 | — | — | US | disclosed |
| EP-4255910-A1 | ALC1 INHIBITORS AND SYNERGY WITH PARPI | Eisbach Bio GmbH (DE) | 2023-10-11 | — | — | EP | disclosed |
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1104759-A1 | Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1104760-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1104758-A1 | Acetylene derivatives as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802112-B2 | Continuous flow micro-total process system for preparation of celecoxib and analogs thereof | PTGES2, PTGS2, CYP2J2 | PLOD2 3454/4885PLOD3 4085/4885PLOD1 4033/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | PLOD2 4308/4885PLOD3 3490/4885PLOD1 4213/4885 |
| US-20240033363-A1 | ALC1 Inhibitors and Synergy with PARPi | PARP11, PARP1, BRCA1 | PLOD2 4236/4885PLOD3 3844/4885PLOD1 3841/4885 |
| US-20220127235-A1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYTEM FOR PREPARATION OF CELCOXIB AND ANALOGS THEREOF | PTGES2, PTGS2, P2RX2 | PLOD2 2433/4885PLOD3 3324/4885PLOD1 3726/4885 |
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | PLOD2 4018/4885PLOD3 1847/4885PLOD1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.